Stock MACK MERRIMACK PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
15.13 USD -0.13% Intraday chart for Merrimack Pharmaceuticals, Inc. -.--% +12.83%
May. 21 Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P Global BMI Index CI
May. 21 Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P TMI Index CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution and Cash Liquidating Dividend Amount of $15.10 per Share of Common Stock
AQ
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
BU
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
BU
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
BU
Merrimack Receives $225 Million Milestone Payment from Ipsen
BU
Merrimack Reports Full Year 2023 Financial Results
BU
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
AQ
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
BU
Merrimack Reports Third Quarter 2023 Financial Results
BU
Merrimack Reports Second Quarter 2023 Financial Results
BU
MERRIMACK PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
 Merrimack Reports First Quarter 2023 Financial Results
BU
MERRIMACK PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
MERRIMACK PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Merrimack Reports Full Year 2022 Financial Results
BU
MERRIMACK PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
MERRIMACK PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Regulation FD Disclosure (form 8-K)
AQ
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
BU
Merrimack Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
AQ
MERRIMACK PHARMACEUTICALS INC : Regulation FD Disclosure, Other Events (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MACK Stock
  4. News Merrimack Pharmaceuticals, Inc.
  5. Press Releases